Acorda Therapeutics Gross Profit vs. Cash And Equivalents

ACORDelisted Stock  USD 16.20  0.40  2.41%   
Based on Acorda Therapeutics' profitability indicators, Acorda Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Acorda Therapeutics' ability to earn profits and add value for shareholders.
For Acorda Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Acorda Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Acorda Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Acorda Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Acorda Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Please note, there is a significant difference between Acorda Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acorda Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acorda Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Acorda Therapeutics Cash And Equivalents vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Acorda Therapeutics's current stock value. Our valuation model uses many indicators to compare Acorda Therapeutics value to that of its competitors to determine the firm's financial worth.
Acorda Therapeutics is rated second in gross profit category among its peers. It is rated below average in cash and equivalents category among its peers creating about  0.25  of Cash And Equivalents per Gross Profit. The ratio of Gross Profit to Cash And Equivalents for Acorda Therapeutics is roughly  3.98 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Acorda Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Acorda Cash And Equivalents vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Acorda Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
82.43 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Acorda Therapeutics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
20.7 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Acorda Cash And Equivalents Comparison

Acorda Therapeutics is currently under evaluation in cash and equivalents category among its peers.

Acorda Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Acorda Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Acorda Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Acorda Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Acorda Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Acorda Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.

Acorda Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Acorda Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Acorda Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Acorda Therapeutics' important profitability drivers and their relationship over time.

Use Acorda Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Acorda Therapeutics Pair Trading

Acorda Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Acorda Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acorda Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acorda Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acorda Therapeutics to buy it.
The correlation of Acorda Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acorda Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acorda Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acorda Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Acorda Therapeutics position

In addition to having Acorda Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs
Theme ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 484 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in Acorda Stock

If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Valuation
Check real value of public entities based on technical and fundamental data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements